SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe1/30/2016 8:55:53 PM
2 Recommendations

Recommended By
civic08801
xr1

  Read Replies (1) of 4474
 
Evidence of pona (in combo with chemo) activity in FLT3+ AML...

Case study of AML patient in relapse after chemo, sorafenib, and stem cell transplant.

"Given that the patient's clone had both the FLT3 and the BCR-ABL1 aberrations ponatinib was added since it is a TKI with dual FLT3 and BCR-ABL1 inhibitory activity ( Table 1). This was given at the standard dose of 45 mg PO daily for a week prior to chemotherapy and at a reduced dose of 15 mg daily during cytotoxic chemotherapy.

"Subsequent bone marrow biopsy prior to the second transplant did not show any morphological or molecular evidence of leukemia. Patient, therefore, underwent conditioning chemotherapy with fludarabine and melphalan (FluMel) prior to a matched unrelated donor allogeneic transplant (MUD-SCT) ( Fig. 1). This was complicated by pancreatitis requiring total parenteral nutrition and supportive care for several weeks. Following this, patient now has been transitioned to an outpatient setting with excellent signs of engraftment and is transfusion independent. Day 30, day 60 and now the 6 month chimerism studies show 100% donor and 0% recipient with no peripheral or bone marrow blasts. Given concerns for high risk for relapse, patient was started on ‘maintenance’ ponatinib 15 mg every other day and continues to be on it~8 months post-SCT. The molecular mRNA BCR-ABL1 testing done continue to show no detectable transcripts in the both the patient's blood and bone marrow."

sciencedirect.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News